In the last trading session, 1.08 million shares of the Tscan Therapeutics Inc (NASDAQ:TCRX) were traded, and its beta was 1.00. Most recently the company’s share price was $1.43, and it changed around $0.05 or 3.62% from the last close, which brings the market valuation of the company to $80.93M. TCRX currently trades at a discount to its 52-week high of $9.29, offering almost -549.65% off that amount. The share price’s 52-week low was $1.02, which indicates that the current value has risen by an impressive 28.67% since then. We note from Tscan Therapeutics Inc’s average daily trading volume that its 10-day average is 1.24 million shares, with the 3-month average coming to 549.13K.
Tscan Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.12. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 0 recommended TCRX as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight.
Tscan Therapeutics Inc (NASDAQ:TCRX) trade information
Instantly TCRX has showed a green trend with a performance of 3.62% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.5000 on recent trading dayincreased the stock’s daily price by 4.67%. The company’s shares are currently down -52.96% year-to-date, but still up 15.32% over the last five days. On the other hand, Tscan Therapeutics Inc (NASDAQ:TCRX) is -10.63% down in the 30-day period. We can see from the shorts that 1.79 million shares have been sold at a short interest cover period of 3.46 day(s).
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 52.33% from its current value. Analyst projections state that TCRX is forecast to be at a low of $3 and a high of $3.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -14.41%. Tscan Therapeutics Inc earnings are expected to increase by -9.10% in 2025, but the outlook is positive 9.18% per year for the next five years.
TCRX Dividends
Tscan Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-05.
Tscan Therapeutics Inc (NASDAQ:TCRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.24% of Tscan Therapeutics Inc shares, and 87.88% of them are in the hands of institutional investors. The stock currently has a share float of 88.09%. Tscan Therapeutics Inc stock is held by 129.0 institutions, with LYNX1 CAPITAL MANAGEMENT LP being the largest institutional investor. By 2024-06-30, it held 4.6062% of the shares, which is about 5.22 million shares worth $30.56 million.
ECOR1 CAPITAL, LLC, with 4.4082% or 5.0 million shares worth $29.25 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and BlackRock Health Sciences Term Trust were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.37 shares worth $1.96 million, making up 2.62% of all outstanding shares. On the other hand, BlackRock Health Sciences Term Trust held roughly 1.05 shares worth around $1.5 million, which represents about 2.00% of the total shares outstanding.
